HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug therapy in Brugada syndrome.

Abstract
Sudden cardiac death in healthy individuals with structurally normal hearts and a characteristic morphology of the QRS complex resembling a right bundle branch block with elevation of the ST segment in V1 to V3 is known as Brugada syndrome (BrS). Although placement of an implantable cardioverter-defibrillator is considered the only effective therapy for symptomatic patients, some authors have repeatedly reported a beneficial effect of quinidine and isoproterenol in patients with BrS. Also, isolated case reports on the usefulness of cilostazol, sotalol, and mexiletine have been described. The present article reviews the mechanisms by which these drugs may act and their role in the pharmacotherapy of BrS. Other possible agents, mainly I(2) blockers, are also reviewed.
AuthorsManlio F Márquez, Gabriel Salica, Antonio G Hermosillo, Gustavo Pastelín, Manuel Cárdenas
JournalCurrent drug targets. Cardiovascular & haematological disorders (Curr Drug Targets Cardiovasc Haematol Disord) Vol. 5 Issue 5 Pg. 409-17 (Oct 2005) ISSN: 1568-0061 [Print] Netherlands
PMID16248833 (Publication Type: Journal Article, Review)
Chemical References
  • Tetrazoles
  • Mexiletine
  • Sotalol
  • Isoproterenol
  • Cilostazol
Topics
  • Bundle-Branch Block (diagnosis, drug therapy, physiopathology)
  • Cilostazol
  • Electrocardiography
  • Humans
  • Isoproterenol (therapeutic use)
  • Mexiletine (therapeutic use)
  • Sotalol (therapeutic use)
  • Syndrome
  • Tetrazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: